NUR 600 Module 5 Assessment Drug PowerPoint Presentation

• NUR 600 Module 5 Assessment Drug PowerPoint Presentation.

Drug PowerPoint Presentation

Slide 1: Hey everyone, I am Elcio Roque. Today, I will lead the conversation and discuss LisLisinopril’s pharmacology and clinical applications. This presentation will discuss LisLisinopril’s use, action, and therapeutic effects in hypertension and heart failure. In addition, pharmacokinetics, side effects, contraindications, and patient education on the drug will also be featured to enhance its safety and efficacy.

Slide 2: Medications are essential to healthcare organizations. They are supposed to treat medical contaminations, alleviate disease signs and side effects, and guarantee positive patient health results. They assist specialists in forestalling complications caused by diseases, managing diseases, and enhancing the quality of life of their patients (Bryniarski et al., 2022). Pharmaceutical activities avert hospitalization and decrease the improvement of valuable diseases, diminishing overall health costs.

For this presentation, I picked Lisinopril, a lisinopril-ed cardiovascular medicinal substance (Bryniarski et al., 2022). Lisinopril is a medication applied for the treatment of More outrageous hypertension and heart failure with the properties of an Angiotensin-Changing over protein (ACE) inhibitor. Lisinopril works by relaxing veins and decreasing heartbeat levels by forestalling ACE.

The Pharmacology and Pharmacokinetics of Lisinopril

Slide 3: Lisinopril focuses on pharmacology and pharmacokinetics concerning the working of the substance in the human body. Lisinopril, an ACE inhibitor, decreases the circulatory strain through vasodilation (Bryniarski et al., 2022). Oral Lisinopril takes about 12-13 hours to clear the body half, has maximal plasma concentration inside about 7 hours, and is the more significant part metabolized in pee.

Pharmacology of Lisinopril

Pharmaceutical science explains how drugs act in the body, and Lisinopril woLisinopriltraining ACE. Angiotensin I is restrained from becoming vasoconstrictor angiotensin II. Therefore, blood arteries dilate, hacking down beats (Albini et al., 2020). Aldosterone, which advances salt and water maintenance, is decreased by Lisinopril, lisinopril blood volume and heartbeat.

Pharmacokinetics of Lisinopril

Slide 4: Pharmacokinetics discusses medication absorption, conveyance, metabolism, and discharge. Lisinopril’s oral bioavailability is around 25%, indicating excellent absorption. Plasma concentrations are a maximum of 7 hours after treatment (Mauricio, 2022). Lisinopril is not liver-metabolized like many medications. It is eliminated unaffected by pee. The elimination half-presence of Lisinopril is Lisinopril, which allows most patients to take it once daily. These key pharmacokinetic properties of Lisinopril are essential considerations in the NUR 600 Module 5 Assessment Drug PowerPoint Presentation, highlighting its absorption, distribution, metabolism, and excretion.

Brand and Generic Name

The generic name is Lisinopril, aLisinoprilincorporate Prinivil and Zestril. The availability of generic and brand-name sorts allows for patient essentials and insurance coverage-based suggestions (Solanki et al., 2023). Lisinopril is adaptable for hypertension and heart failure because its advantages and dangers are steady across generic and brand-name forms.

Dosing

Lisinopril dosage depends upon the situation and the patient’s reaction. Hypertension usually starts with 10 mg daily. The maintenance area is 20-40 mg once daily, dependent upon the patient’s heartbeat reaction (Savarese et al., 2021). For heart failure, start with 5 mg one time each day and titrate up to 20-40 mg based on clinical reaction and tolerance. Dosing modifications could avoid harm in renally impaired patients.

Indications for Use

Slide 5: Lisinopril has several critical clinical uses. Lisinopril is used for various purposes that are essential to human health. Primarily for hypertension patients, it assists with forestalling strokes and heart attacks. This is also beneficial to liberating side effects and decreasing the re-hospitalization rate of patients diagnosed with symptomatic heart failure. Lisinopril enhances the strength of heart muscle and reduces the repeat of further cardiac occasions following a myocardial infarction, leading to the advancement of survival rates (Jering et al., 2021).

NUR 600 Module 5 Assessment Drug PowerPoint Presentation

These ways switch and forestall the decrease in kidney capability in type 1 DN patients based on a decline in heart rate and proteinuria. Lisinopril plays an essential role in the treatment of cardiovascular diseases. It controls the heart rate since it impacts the compound called angiotensin, changes protein, and enhances the heart’s working and Caveney capabilities among diabetic patients (Jering et al., 2021).

The information on its pharmacodynamics, pharma, dosages and treatment indications will deal with its utilization and patients’ advantages. Patients ought to be informed by their healthcare suppliers about their drugs and their effects, and treatment ought to be altered to gain optimal outcomes.

Analysis and Evaluation of the Issue

Slide 6: To assess the issue, several aspects of Lisinopril you Lisinopril examined. Side effects, contraindications, cost, and pregnancy class are assessed (Sliwa et al., 2021). Healthcare practitioners should understand these characteristics to propose and manage Lisinopril medication for patients.

Side Effects

Adverse effects are those negative effects of a drug on the patient’s flourishing, as with any competitor, lisinopril haLisinoprilects. This category includes side effects incorporating daze, headache, fatigue, and hacks. This is usually moderate and disappears as the body finds a guaranteed sensation of harmony with the medication. Side effects allude to adverse opinions or senses experienced while on medication. Regardless, a great deal of, like any drug, Lisinopril alLisinoprilesirable side effects associated with it. It has been found in the US that patients complain of a dry hack that happens for some time and may lead to fix stoppage (Ojha et al., 2021).

Lisinopril Side Effects Overview

Other outrageous side effects of Lisinopril include an increase in potassium levels in the blood, hyperkalemia, Angioedema, Low heartbeat or hypotension, and renal complications such as impaired renal capability. Hyperkalemia can lead to various cardiac musicality disturbances if it is not checked. Angioedema is the expansion of the more profound layers of the skin in the areas of the face, around the eyes, and the lips.

It can be hazardous, assuming that it affects the airways. Another issue associated with its use is hypotension, particularly in volume exhaustion or patients getting antihypertensives (Ojha et al., 2021). It is rare; renal impairment means kidney capabilities should be checked periodically, particularly for patients with renal diseases.

Contraindications

Contraindications are conditions or factors that prevent a patient from searching for a treatment inferable from adverse effects. Lisinopril is contraindicated in specific individuals because of significant side effects. For example, ACE should avoid Lisinopril inhibitor-treated angioedema patients (Ahmad et al., 2023). The US advises avoiding taking Lisinopril; Lisinopril had angioedema with another ACE inhibitor because of the chance of a repeat.

It can deteriorate hereditary or idiopathic angioedema; accordingly, Lisinopril is shLisinopriloided. Another contraindication is outrageous precariousness to Lisinopril or its parts (Ahmad et al., 2023). The danger of fetal damage makes Lisinopril unLisinopriluring during pregnancy. Pregnant and attempting ladies should not use the medication since it can harm or kill the hatchling.

Cost Analysis

Slide 7: When calculating the cost of medication, it is essential to consider factors like where you reside, your insurance strategy, and whether you are purchasing a generic or brand-name variant. Lisinopril costs fluctuate broadly—the generic adaptation of Lisinopril is in the US (Venechuk et al., 2020). Generic Lisinopril coLisinopril is available monthly, making it affordable for many individuals.

Regardless, Prinivil and Zestril cost $20 to $50 monthly. Insurance coverage significantly affects patient personal payments. Patients save cash on generic Lisinopril because lisinopril insurance plans cover it (Venechuk et al., 2020). Many healthcare practitioners and patients appreciate the generic interpretation because of its lower cost, allowing appropriate hypertension management without financial hardship.

Pregnancy Class

Pregnancy classes show a drug’s gamble of birth abnormalities or other adverse effects during pregnancy. The FDA classifies Lisinopril as Lisinopril Category D. Adverse reaction data proposes a human fetal gamble, although the potential advantages in pregnant ladies may offset these worries (Venechuk et al., 2020). In the US, specialists advise against giving Lisinopril toLisinoprilladies attributable to stress. Studies demonstrate that Lisinopril causes renal failure, bone deformities, and mortality.

Before endorsing Lisinopril toLisinoprilladies, a gamble-benefit analysis is essential. More safe drugs are advised during pregnancy. Lisinopril is a popular ACE inhibitor that treats hypertension and heart failure. Similarly to other medications, it can cause dizziness, headache, fatigue, hack, hyperkalemia, angioedema, hypotension, and renal impairment (Festa et al., 2020).

A background marked by ACE inhibitor-related angioedema, hereditary or idiopathic, past staggering responsiveness, and pregnancy are contraindications. Generic Lisinopril Lisinopril and more generally available in the US than its brand-name counterparts. The dangers to the baby make Lisinopril Pregnancy Category D; therefore, it ought to be avoided aside from at whatever point required. Healthcare practitioners should understand these characteristics to use Lisinopril to decrease gambles safely.

Demonstrates a Conceptual Understanding

Slide 8: Understanding Lisinopril requires information on its pharmacology, clinical uses, and patient care implications. This requires an exhaustive knowledge of Lisinopril’s Lisinopril and its side effects (Festa et al., 2020). It also requires analyzing evidence-based examinations to support its therapeutic use and explaining how healthcare suppliers like Nurse Practitioners propose and screen Lisinopril—conceptual appreciation guarantees able and informed Lisinopril cardiovascular health management choices.

Overview of Patient Case Study

The 60-year-old John Doe has hypertension and type 2 diabetes. John in New York City has inadequately managed circulatory strain despite taking hydrochlorothiazide. His kidney impairment began with early-stage diabetic nephropathy, which he was diagnosed with as of late. His hypertension, averaging 160/100 mmHg, really jeopardizes him for cardiovascular issues and kidney damage.

Case Study Drug Utilization

Because of John’s hypertension and diabetic nephropathy, Lisinopril decreases circulatory strain and safeguards the kidneys. John reliably starts at 10 milligrams. Bringing his heartbeat under 130/80 mmHg, hacking down proteinuria, and stabilizing renal capability will halt nephropathy advancement (Rahman et al., 2020). Initially, John takes regular follow-ups and lab testing to assess beat reaction and renal capability, including serum creatinine and potassium levels. This exhaustive monitoring guarantees that the drug works and addresses side effects like hyperkalemia.

Evidence-Based Research

Slide 9: He et al. (2020) conveyed a significant Journal of Medication study on Lisinopril and Lisinopril nephropathy improvement. Lisinopril was pursued for its ability to slow renal damage in type 1 and type 2 diabetics. The 5-year randomized controlled trial of 573 individuals showed that Lisinopril deLisinoprilnal disease improved by 28% compared to a benchmark group. In Lisinopril patients, serum creatinine increased considerably more slowly, and dialysis or kidney transplantation was more uncertain (He et al., 2020).

According to the study, Lidinoprilantidiabetic medication treats diabetic nephropathy since it assists with safeguarding renal capabilities. Francischetti et al. (2020). American Journal of Cardiovascular Drugs aimed to compare Lisinopril onLisinoprilase of circulatory strain and the cardiovascular gamble in patients with hypertension. The study lasted four years and drove a random control trial of Lisinopril toLisinopril200 hypertension individuals.

Lisinopril brought the beat down to 155/90 mmHg with a decrease in systolic and diastolic circulatory strain by 15 and 10 mmHg. Compared to the benchmark group, the study participants who took Lisinopril had a 20% decrease in the number of cardiovascular occasions, such as heart attacks and strokes. Based on the evidence framed above, Lisinopril is the first-line drug decision for hypertension and has cardiovascular advantages.

Nurse Practitioner

As a Nurse Practitioner (NP), I implement a different approach for the continuous development of John’s health. First, a complete health assessment of John is conducted. The medical history, current medications and lifestyle factors are studied. It is critical for John to understand these factors before developing an appropriate treatment plan. John was advised to Lisinopril,he guaranteed it. This includes teaching him about Lisinopril, Lisinopril gas, and compliance (Francischetti et al., 2020).

Frequent Lisinopril ordination for ideal circulatory strain control and kidney insurance To avoid the issues of hypertension and diabetic nephropathy, John should take the medications regularly, even if he feels gotten to a more elevated level.

Education Involves Explaining Potential Side Effects

Patient education is essential for functional drug management. I run through things like dizziness, headache, fatigue, and coughing, all common side effects I expect John to experience. I would also monitor for serious side effects such as hyperkalemia, angioedema, and hypotension (Francischetti et al. John should call me right now if he has facial or peripheral edema, trouble respiratory function, or egregious bradycardias. Instead, this proactive strategy sees and manages harmful effects early on to protect John.

Routine follow-ups monitor John’s progress. These visits assess his heartbeat, kidney function and electrolytes. As I monitor these, I have the ability to adjust his medication up or down based on his response and experimental findings. A predictable monitoring allows to achieve therapeutic targets with a less risk of side effects (Albini et al., 2020). I am a Nurse Practitioner who collaborates with endocrinologists and nephrologists. This cross-pollination wraps up John’s kidney-and-diabetes care. John’s needs are all handled by communicating with these specialists, it sorts out his care.

Patient Education

Slide 11: Patient education is critical to Lisinopril efficacy and safety. Patients are provided with extensive information on their drug’s motivation, dosing norm, side effects, and compliance (Kvarnström et al., 2021). Patients ought to be taught how to observe and handle anticipated side effects and when to look for medical help in case of severe side effects. In order to further develop drug efficacy, diet and exercise should be taken into consideration. Patient education allows patients to control their health and further generates treatment outcomes.

Medication Adherence

Emphasize the necessity to take Lisinopril daLisinoprilised in order to ensure medication compliance. John must understand that consistent medication is needed in order to manage his heartbeat and protect his kidneys (Kvarnström et al., 2021). Missing dosages may result in swings in heartbeat and complications.

Monitoring Side Effects

Making sure attention is drawn to potential side effects and their side effects is important. If daze, headache, tiredness, or hack persists, make sure they are informed (O’Donovan et al., 2022). Angioedema, swelling of the body, and other severe reactions require prompt medical attention. John can take early action to avoid effects by identifying signs of side effects.

Lifestyle Modifications

Slide 12: Lifestyle modification is necessary in the control of hypertension and diabetic nephropathy. I advise John to have a low-sodium diet in order to reduce his circulatory load (O’Donovan et al., 2022). Walking or cycling as forms of regular exercise controls cardiovascular condition and heart rate. Lisinopril works better and creates additional health if alcohol and cigarette smoking are avoided.

Regular Monitoring

My suggestion is to have regular follow-up meetings to monitor John’s heartbeat, kidney function, and electrolytes. The frequent visits are crucial for assessment of Lisinopril efficacy and dosage titration (Solanki et al., 2023). Regular monitoring guarantees medication efficacy and early identification of stresses.

Monitoring and Follow-Up

Slide 13: Lisinopril follow-up and therapeutic monitoring are essential to patient success. Beat, renal function, and electrolytes are measured to evaluate drug safety and efficacy. Regular blood tests track kidney function and electrolyte balance (Solanki et al., 2023). Follow-up allows specialists to modify Lisinopril dosage based on patient response and test results. Monitoring also detects and treats side effects early, improving patient safety and drug efficacy.

Beat: Circulatory pressure must be checked regularly to ascertain that Lisinopril is hypertension. Regular checks determine the drug’s viability and make any suitable dosage adjustments.

Renal Capability: Kidney Function: The BUN and serum creatinine must be regularly tested to screen kidney function (Kim et al., 2021). This screening closes Lisinopril meLisinoprilhn’s kidneys, particularly given his stage-one diabetic nephropathy.

Electrolytes: Electrolytes: Potassium should be monitored routinely for early detection of hyperkalemia. Elevated potassium is harmful to the heart. Hence, screening them frequently is critical to provide prompt action if required.

Follow-Up Appointments:  Follow-Up Visits: John should originally schedule follow-up visits for some fourteen days. His electrolytes and renal functioning will all be assessed during visits (Kim et al., 2021). After his situation becomes more active, month to month checkups may be the repetition of visits. Based on his test scheduling and clinical response, I shall monitor John’s improvement at each visit, identify any problems, and change Lisinopril dosage as the case may dictate. This method guarantees proper medication management, which is in compliance with the goals of the NUR 600 Module 5 Assessment Drug PowerPoint Presentation.

References

Ahmad, H., Khan, H., Haque, S., Ahmad, S., Srivastava, N., & Mohd Azhar Khan. (2023). Angiotensin-converting enzyme and hypertension: A systemic analysis of various ace inhibitors, their side effects, and bioactive peptides as a putative therapy for hypertension. Journal of the Renin-Angiotensin-Aldosterone System, 2023(6), 1–9. https://doi.org/10.1155/2023/7890188

Albini, A., Di Guardo, G., Noonan, D. M., & Lombardo, M. (2020). The SARS-CoV-2 receptor, ACE-2, is expressed on many cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies. Internal and Emergency Medicine, 15(5), 759–766. https://doi.org/10.1007/s11739-020-02364-6

Bryniarski, P., Nazimek, K., & Marcinkiewicz, J. (2022). Immunomodulatory activity of the most commonly used antihypertensive drugs, angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers. International Journal of Molecular Sciences, 23(3), 1772. https://doi.org/10.3390/ijms23031772

Festa, M., Sansone, C., Brunet, C., Crocetta, F., Di Paola, L., Lombardo, M., Bruno, A., Noonan, D. M., & Albini, A. (2020). Cardiovascular active peptides of marine origin with ace inhibitory activities: Potential Role as antihypertensive drugs and in preventing sars-cov-2 infection. International Journal of Molecular Sciences, 21(21), 8364. https://doi.org/10.3390/ijms21218364

Francischetti, E. A., de Abreu, V. G., da Silva Figueiredo, L. F., Dezonne, R. S., & Coutinho, E. S. F. (2020). Effects of blood pressure lowering agents on cardiovascular outcomes in weight excess patients: A systematic review and meta-analysis. American Journal of Cardiovascular Drugs, 5(3). https://doi.org/10.1007/s40256-019-00393-x

He, D., Zhang, Y., Zhang, W., Xing, Y., Guo, Y., Wang, F., Jia, J., Yan, T., Liu, Y., & Lin, S. (2020). Effects of ace inhibitors and angiotensin receptor blockers in normotensive patients with diabetic kidney disease. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones et Metabolisme, 52(5), 289–297. https://doi.org/10.1055/a-1138-0959

Jering, K. S., Claggett, B., Pfeffer, M. A., Granger, C., Køber, L., Lewis, E. F., Maggioni, A. P., Mann, D., McMurray, J. J. V., Rouleau, J., Solomon, S. D., Steg, P. G., Meer, P., Wernsing, M., Carter, K., Guo, W., Zhou, Y., Lefkowitz, M., Gong, J., & Wang, Y. (2021). Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction ( PARADISE‐MI ): Design and baseline characteristics. European Journal of Heart Failure, 7(4). https://doi.org/10.1002/ejhf.2191

Kim, H. J., Kim, T. E., Han, M., Yi, Y., Jeong, J. C., Chin, H. J., Song, S. H., Lee, J., Lee, K.-B., Sung, S., Han, S. H., Seong, E. Y., Ahn, C., Oh, K.-H., & Chae, D.-W. (2021). Effects of blood urea nitrogen independent of the estimated glomerular filtration rate on the development of anaemia in non-dialysis chronic kidney disease: The results of the KNOW-CKD study. PloS One, 16(9). https://doi.org/10.1371/journal.pone.0257305

Kvarnström, K., Westerholm, A., Airaksinen, M., & Liira, H. (2021). Factors contributing to medication adherence in patients with a chronic condition: A Scoping review of qualitative research. Pharmaceutics, 13(7). https://doi.org/10.3390/pharmaceutics13071100

Mauricio. (2022). Publicación de Documentación Digital – UMSS: hiperplasia endometrial quística / piómetra en caninos, en el hospital clínico veterinario pet-home del municipio de Quillacollo. Umss.edu.bo, 5(5). http://hdl.handle.net/123456789/27755

O’Donovan, B., Rodgers, R. M., Cox, A . R., & Krska, J. (2022). Identifying and managing adverse drug reactions: Qualitative analysis of patient reports to the UK yellow card scheme. British Journal of Clinical Pharmacology, 88(7). https://doi.org/10.1111/bcp.15263

Ojha, U., Ruddaraju, S., Sabapathy, N., Ravindran, V., Worapong Atitaya, P., Haq, J., Mohammed, R., & Patel, V. (2021). Current and emerging classes of pharmacological agents for the management of hypertension. American Journal of Cardiovascular Drugs, 22(6). https://doi.org/10.1007/s40256-021-00510-9

Rahman, M., Drawz, P., Thomas, G., & Turner, J. (2020, January 1). Chapter 61 – management of hypertension in chronic kidney disease (P. L. Kimmel & M. E. Rosenberg, Eds.). ScienceDirect; Academic Press.  https://www.sciencedirect.com/science/article/pii/B9780128158760000619

Savarese, G., Bodegard, J., Norhammar, A., Sartipy, P., Thuresson, M., Cowie, M. R., Fonarow, G. C., Vaduganathan, M., & Coats, A. J. S. (2021). Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: A multinational observational study ( US, UK and Sweden). European Journal of Heart Failure, 23(9), 1499–1511. https://doi.org/10.1002/ejhf.2271

Sliwa, K., Meer, P., Petrie, M. C., Fragoudaki, A., Johnson, M. R., Hilfiker‐Kleiner, D., Hamdan, R., Jackson, A. M., Ibrahim, B., Mbakwem, A., Tschöpe, C., Regitz‐Zagrosek, V., Omerovic, E., Roos‐Hesselink, J., Gatzoulis, M., Tutarel, O., Price, S., Heymans, S., Coats, A. J. S., & Müller, C. (2021). Risk stratification and management of women with cardiomyopathy/heart failure planning a pregnancy or presenting during/after pregnancy: A position statement from the heart failure association of the European Society of Cardiology study group on peripartum cardiomyopathy. European Journal of Heart Failure, 23(4), 527–540. https://doi.org/10.1002/ejhf.2133

Solanki, D., Dhonnar, R., Shinde, R., Shelar, S., & Shirke, V. (2023). Review of different approaches to nanotechnology for cardiovascular diseases. Certified Journal │ Deep et Al. World Journal of Pharmaceutical Research, 12(6). https://doi.org/10.20959/wjpr202322-30432

Venechuk, G. E., Allen, L. A., Doermann Byrd, K., Dickert, N., & Matlock, D. D. (2020). Conflicting perspectives on the value of neprilysin inhibition in heart failure were revealed during the development of a decision aid focusing on patient costs for sacubitril/valsartan. Circulation: Cardiovascular Quality and Outcomes, 13(9). https://doi.org/10.1161/circoutcomes.119.006255